{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:22:23Z","timestamp":1742703743156,"version":"3.40.2"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.leukres.2025.107673","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:13:33Z","timestamp":1740672813000},"page":"107673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-1265","authenticated-orcid":false,"given":"Vu Thi","family":"Thuy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Linh","family":"Viet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Trong","family":"Nghia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Cangelosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-5430","authenticated-orcid":false,"given":"Cuc Thi Thu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib1","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2025.107673_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107673_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"6","key":"10.1016\/j.leukres.2025.107673_bib5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2025.107673_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107673_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107673_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.leukres.2025.107673_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"issue":"11-12","key":"10.1016\/j.leukres.2025.107673_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","article-title":"The genetic landscape of the human solute carrier (SLC) transporter superfamily","volume":"138","author":"Schaller","year":"2019","journal-title":"Hum. Genet."},{"issue":"12","key":"10.1016\/j.leukres.2025.107673_bib12","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107673_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","article-title":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","volume":"51","author":"da Cunha Vasconcelos","year":"2016","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2025.107673_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium","volume":"104","author":"Yee","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.leukres.2025.107673_bib15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia","volume":"121","author":"Giannoudis","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107673_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mgene.2016.11.002","article-title":"Association of genetic polymorphisms of the ABCG2, ABCB1, SLCO1B3 genes and the response to Imatinib in chronic myeloid leukemia patients with chronic phase","volume":"11","author":"Nair","year":"2017","journal-title":"Meta Gene"},{"issue":"3","key":"10.1016\/j.leukres.2025.107673_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1179\/1607845414Y.0000000181","article-title":"Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients","volume":"20","author":"de Lima","year":"2015","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.leukres.2025.107673_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/labmed\/lmab023","article-title":"Association of SLC22A1,SLCO1B3 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in patients with chronic myeloid leukemia","volume":"52","author":"Mohammadi","year":"2021","journal-title":"Lab Med."},{"issue":"11","key":"10.1016\/j.leukres.2025.107673_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/jpps30559","article-title":"Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in chinese patients with chronic myeloid leukemia","volume":"23","author":"Wang","year":"2020","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13046-017-0523-3","article-title":"Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment","volume":"36","author":"Jaruskova","year":"2017","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2025.107673_bib22","doi-asserted-by":"crossref","unstructured":"A.M.A. G\u00f3mez, M.A. D\u00edaz-Mendoza, Y.B. Lemus, G. Le\u00f3n-Mej\u00eda, M.L.R. BenitezPolymorphisms in drug transporter and metabolism genes associated with resistance to imatinib in chronic myeloid leukemia: a systematic review and meta-analysis, 92(1), 2024, p. 2.","DOI":"10.3390\/scipharm92010002"},{"key":"10.1016\/j.leukres.2025.107673_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"131","author":"Cargnin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.leukres.2025.107673_bib24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.leukres.2025.107673_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"year":"2021","series-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"Harrer","key":"10.1016\/j.leukres.2025.107673_bib26"},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"Int. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107673_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jclinepi.2007.12.011","article-title":"Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches","volume":"61","author":"Zintzaras","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"7109","key":"10.1016\/j.leukres.2025.107673_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.leukres.2025.107673_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","author":"de Lima","year":"2014","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107673_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","article-title":"The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia","volume":"14","author":"Di Paolo","year":"2014","journal-title":"Pharmacogen. J."},{"issue":"8","key":"10.1016\/j.leukres.2025.107673_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","article-title":"Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib","volume":"32","author":"Francis","year":"2015","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107673_bib33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12591","article-title":"A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia","volume":"163","author":"Grinfeld","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107673_bib34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2025.107673_bib35","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12041-018-0978-9","article-title":"Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients","volume":"97","author":"Makhtar","year":"2018","journal-title":"J. Genet."},{"key":"10.1016\/j.leukres.2025.107673_bib36","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3389\/fonc.2020.01348","article-title":"Association of the trough, peak\/trough ratio of imatinib, pyridine-N-oxide imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G with imatinib response in egyptian chronic myeloid leukemia patients","volume":"10","author":"Omran","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.107673_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.leukres.2025.107673_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","article-title":"Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in chronic myeloid leukemia","volume":"765","author":"Vaidya","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107673_bib39","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2025.107673_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2025.107673_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","article-title":"Do SLCO1B3 (T334G) and CYP3A5*\u20093 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?","volume":"18","author":"Bedewy","year":"2013","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.leukres.2025.107673_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","article-title":"hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia","volume":"79","author":"Ben Hassine","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.leukres.2025.107673_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100277","article-title":"Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: a therapeutic goal has been reached","volume":"19","author":"Breccia","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.leukres.2025.107673_bib44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.leukres.2025.107673_bib45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2025.107673_bib46","doi-asserted-by":"crossref","unstructured":"Y. LaiOrganic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs, OCTs, OCTNs and MATEs), 2013, pp. 455-631.","DOI":"10.1533\/9781908818287.455"},{"issue":"27","key":"10.1016\/j.leukres.2025.107673_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011349","article-title":"Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: a systematic review","volume":"97","author":"Mofo Mato","year":"2018","journal-title":"Medicine"},{"issue":"12","key":"10.1016\/j.leukres.2025.107673_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051771","article-title":"SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia","volume":"7","author":"Singh","year":"2012","journal-title":"PLOS One"},{"issue":"11","key":"10.1016\/j.leukres.2025.107673_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/gm206","article-title":"The pharmacogenetics of imatinib","volume":"2","author":"Dulucq","year":"2010","journal-title":"Genome Med."},{"issue":"8","key":"10.1016\/j.leukres.2025.107673_bib50","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2025.107673_bib51","first-page":"2043","article-title":"Molecular response to imatinib and its correlation with mRNA expression levels of imatinib influx transporter (OCT1) in Indian chronic myeloid leukemia patients","volume":"18","author":"Chhikara","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.leukres.2025.107673_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0976-500X.149141","article-title":"Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: a single-center surveillance study","volume":"6","author":"Francis","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"17","key":"10.1016\/j.leukres.2025.107673_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179815","article-title":"Genetic variants of ABC and SLC transporter genes and chronic myeloid leukaemia: impact on susceptibility and prognosis","volume":"23","author":"Alves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.leukres.2025.107673_bib55","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00280-015-2905-6","article-title":"A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients","volume":"76","author":"Francis","year":"2015","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:50:41Z","timestamp":1742673041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":55,"alternative-id":["S0145212625000335"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107673","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107673"}}